Stock Updates

A look at a High Market Cap Stock: GlaxoSmithKline plc, GSK

GlaxoSmithKline plc, GSK is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in United Kingdom, GlaxoSmithKline plc, GSK  has a market cap of 104934.18. Since its IPO date on the 07/09/1986, GlaxoSmithKline plc, GSK performance year to date is 11.85%. Today GlaxoSmithKline plc, GSK has gained 0.76%, with a current price of 43.5.

Ownership of the company is 0.20% for insider ownership while institutional ownership is 8.90%. The management of the company have seen the company have a payout ratio of 629.40%. Return of assets are at 1.10%, with return on investment at 41.40%.

In terms of debt levels and profit levels, GlaxoSmithKline plc, GSK is seeing a long-term debt/equity of 5.61. While Total debt/equity is 6.05. With a profit margin of 2.50%, this is combined with a gross margin of 66.40%, and operating margin of 7.50%. GlaxoSmithKline plc ability to meet debt levels, with a current ratio of 1.1, while the quick ratio is 0.8.

For the last year GlaxoSmithKline plc, GSK has seen a EPS growth of 204.10%. A performance for the year of 9.76%. The 52-week high is 0.37%, and the 52-week low is 23.85%. The average volume for GlaxoSmithKline plc, GSK is 2811648.

With a target price of 47, can GlaxoSmithKline plc, GSK reach this target? Looking at the value indicators of GlaxoSmithKline plc, GSK. GlaxoSmithKline plc has a P/E of 129.25 and a forward P/E of 16.51. Perhaps the more useful indicator than P/E, is PEG which has a value of 215.42. GlaxoSmithKline plc also has a P/S and a P/B of 3.21 and 28.03 respectively. For P/cash, GlaxoSmithKline plc has a value of 17.58, while it is *TBA for P/free cash flow.

At the current price of 43.5, GlaxoSmithKline plc has a dividend yield of 5.14%. We see a return on equity of 12.20%.

Looking more long-term GlaxoSmithKline plc, is projected to get an EPS growth for the next five years of 0.60%. In the short-term an EPS growth of 12.87% in the next year is forecasted. This is after a EPS growth of 204.10% for this year and for the last five years a 40.20% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Tony Dabbs

Leave a Comment